MimiI-NanHuMD

PubMed

• Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer.
  Gouda, M., Iorgulescu, J., Shen, T., Wu, J., Subbiah, V., Dadu, R., Patel, K., Sherman, S., Cabanillas, M., Hu, M., Castellanos, L., Amini, B., Meric-Bernstam, F.> ;NPJ Precision Oncology. 2024 Mar 4
• Pediatric Medullary Thyroid Carcinoma: Clinical Presentations and Long-term Outcomes in 144 Patients Over Six Decades.
  Bassett, R., Zafereo, M., Hyde, S., Hensley, S., Hu, M., Ying, A., Perrier, N., Busaidy, N., Grubbs, E., Waguespack, S.> ;The Journal of Clinical Endocrinology and Metabolism. 2024 Mar 4
• RET kinase inhibitors for the treatment of RET-altered thyroid cancers: Current knowledge and future directions.
  Hamidi, S., Hu, M.> ;Annales D'endocrinologie. 2024 Feb 9
• 1 citations
  Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancers.
  Lambdin, J., Zafereo, M., Sarvestani, A., Hu, M., Cabanillas, M., Waguespack, S., Hernandez, J.> ;Annals of Surgical Oncology. 2024 Apr 1
• Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study.
  Subbiah, V., Hu, M., Mansfield, A., Taylor, M., Schuler, M., Zhu, V., Hadoux, J., Curigliano, G., Wirth, L., Gainor, J., Alonso, G., Adkins, D., Godbert, Y., Ahn, M., ...> ;Thyroid. 2024 Jan 1
• 1 citations
  Strategies for mitigating adverse events related to selective RET inhibitors in patients with RET-altered cancers.
  Gouda, M., Barreto, C., Slade, J., Poullard, A., Zafereo, M., Nardo, M., Nelson, B., Hu, M., Cabanillas, M., Subbiah, V.> ;Cell Reports. Medicine. 2023 Dec 19
• Decreasing utilization for postoperative radiation therapy in locoregionally advanced medullary thyroid cancer.
  Anastasios Maniakas, Andrew Sullivan, Mimi I Hu, Naifa L Busaidy, Maria E Cabanillas, Ramona Dadu, Steven G Waguespack, Sarah B Fisher, Paul H Graham, Neil D Gross, El...> ;Head & Neck. 2024 Feb 1
• Fusion Identified in a Patient with Medullary Thyroid Carcinoma.
  Omar Alsharif, Timothy Panella, Laurentia Nodit, Mimi I Hu> ;Thyroid. 2023 Jun 1
• 5 citations
  Review article: new treatments for advanced differentiated thyroid cancers and potential mechanisms of drug resistance.
  Sarah Hamidi, Marie-Claude Hofmann, Priyanka C Iyer, Maria E Cabanillas, Mimi I Hu, Naifa L Busaidy, Ramona Dadu> ;Frontiers in Endocrinology. 2023 Jan 1
• 10 citations
  Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline.
  Ghada El-Hajj Fuleihan, Gregory A Clines, Mimi I Hu, Claudio Marcocci, M Hassan Murad, Thomas Piggott, Catherine Van Poznak, Joy Y Wu, Matthew T Drake> ;The Journal of Clinical Endocrinology and Metabolism. 2023 Feb 15
• 11 citations
  Neoadjuvant Selective RET Inhibitor for Medullary Thyroid Cancer: A Case Series.
  Kevin J Contrera, Maria K Gule-Monroe, Mimi I Hu, Maria E Cabanillas, Naifa L Busaidy, Ramona Dadu, Steven G Waguespack, Jennifer R Wang, Anastasios Maniakas, Stephen ...> ;Thyroid. 2023 Jan 1
• 12 citations
  LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve-mutant medullary thyroid cancer.
  Lori J Wirth, Marcia S Brose, Rossella Elisei, Jaume Capdevila, Ana O Hoff, Mimi I Hu, Makoto Tahara, Bruce Robinson, Ming Gao, Meng Xia, Patricia Maeda, Eric Sherman> ;Future Oncology. 2022 Sep 1
• 17 citations
  RET kinase inhibitors for-altered thyroid cancers.
  Danica M Vodopivec, Mimi I Hu> ;Therapeutic Advances in Medical Oncology. 2022 Jan 1
• 5 citations
  Hypercalcemia of Malignancy.
  Mimi I. Hu> ;Endocrinology and Metabolism Clinics of North America. 2021 Dec 1
• 6 citations
  Medullary thyroid carcinoma.
  Tania Jaber, Ramona Dadu, Mimi I. Hu> ;Current Opinion in Endocrinology, Diabetes, and Obesity. 2021 Oct 1
• 134 citations
  Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study
  Vivek Subbiah, Mimi I. Hu, Lori J. Wirth, Martin Schuler, Aaron S. Mansfield, Giuseppe Curigliano, Marcia S. Brose, Viola W. Zhu, Sophie Leboulleux, Daniel W. Bowles, ...> ;The Lancet. Diabetes & Endocrinology. 2021 Aug 1
• 3 citations
  Decision Making When Cancer Becomes Chronic: Needs Assessment for a Web-Based Medullary Thyroid Carcinoma Patient Decision Aid.
  Danielle Shojaie, Aubri S. Hoffman, Ruth Amaku, Maria E. Cabanillas, Julie Ann Sosa, Steven G. Waguespack, Mark Zafereo, Mimi I. Hu, Elizabeth E. Grubbs> ;JMIR Formative Research. 2021 Jul 16
• 26 citations
  Afirma Genomic Sequencing Classifier and Xpression Atlas Molecular Findings in Consecutive Bethesda III-VI Thyroid Nodules.
  Mimi I. Hu, Steven G. Waguespack, Chrysoula Dosiou, Paul W. Ladenson, Masha J. Livhits, Lori J. Wirth, Peter M. Sadow, Jeffrey F. Krane, Brendan C. Stack, Mark Zafereo...> ;The Journal of Clinical Endocrinology and Metabolism. 2021 Jul 13
• 18 citations
  Immune checkpoint inhibitor related hypophysitis: diagnostic criteria and recovery patterns.
  Ha Nguyen, Komal Shah, Steven G. Waguespack, Mimi I. Hu, Mouhammed Amir Habra, Maria E. Cabanillas, Naifa L. Busaidy, Roland L. Bassett, Shouhao Zhou, Priyanka C. Iyer...> ;Endocrine-Related Cancer. 2021 Apr 1
• 7 citations
  Adverse events associated with bone-directed therapies in patients with cancer.
  Mark Anthony Jara, Jeena Varghese, Mimi I. Hu> ;Bone. 2021 Feb 22
• 115 citations
  Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations
  Vivek Subbiah, Tao Shen, Simon Terzyan, Xuewu Liu, Xueqing Hu, Keyur P. Patel, Mimi Hu, Maria E. Cabanillas, Amini Behrang, Funda Meric-Bernstam, P.T.T. Vo, Blaine H. ...> ;Annals of Oncology. 2021 Feb 1
• 31 citations
  Neoadjuvant selpercatinib for advanced medullary thyroid cancer.
  Yelda Jozaghi, Mark Zafereo, Michelle D. Williams, Maria Gule-Monroe, Jennifer Wang, Elizabeth G. Grubbs, Ara A. Vaporciyan, Mimi I. Hu, Naifa L. Busaidy, Ramona Dadu,...> ;Head & Neck. 2021 Jan 1
• 3 citations
  Osteonecrosis of the jaw risk factors in bisphosphonate-treated patients with metastatic cancer.
  Catherine Van Poznak, Evan L. Reynolds, Cherry L. Estilo, Mimi Hu, Bryan P. Schneider, Daniel L. Hertz, Christina L. Gersch, Jacklyn N. Thibert, Dafydd G. Thomas, Mous...> ;Oral Diseases. 2020 Dec 4
• 41 citations
  Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies.
  Aparna Hegde, Alexander Y. Andreev-Drakhlin, Jason Roszik, Le Huang, Shuang Liu, Kenneth R. Hess, Maria E. Cabanillas, Mimi I. Hu, Naifa L. Busaidy, Steven I. Sherman,...> ;ESMO Open. 2020 Jan 1
• 5 citations
  HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: The state of science in medullary thyroid carcinoma: current challenges and unmet needs
  Ramona Dadu, Rozita Bagheri-Yarmand, Matthew D. Ringel, Elizabeth G. Grubbs, Mark Zafereo, Gilbert J. Cote, Robert F. Gagel, Bruce G. Robinson, Kenna R. Shaw, Mimi I. Hu> ;Endocrine-Related Cancer. 2020 Aug 1
• Join now to see all